Next Article in Journal
Next Article in Special Issue
Previous Article in Journal
Previous Article in Special Issue
Cancers 2011, 3(2), 2444-2461; doi:10.3390/cancers3022444
Review

Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer

1,* , 1
, 1
, 1
, 1
, 1
, 1
, 1,2
 and 1
Received: 20 April 2011; in revised form: 6 May 2011 / Accepted: 12 May 2011 / Published: 18 May 2011
(This article belongs to the Special Issue Cancer Signaling Pathways and Crosstalk)
View Full-Text   |   Download PDF [360 KB, updated 19 May 2011; original version uploaded 18 May 2011]
Abstract: Hepatocarcinogenesis is a complex multistep process in which many different molecular pathways have been implicated. Hepatocellular carcinoma (HCC) is refractory to conventional chemotherapeutic agents, and the new targeted therapies are meeting with limited success. Interreceptor crosstalk and the positive feedback between different signaling systems are emerging as mechanisms of targeted therapy resistance. The identification of such interactions is therefore of particular relevance to improve therapeutic efficacy. Among the different signaling pathways activated in hepatocarcinogenesis the epidermal growth factor receptor (EGFR) system plays a prominent role, being recognized as a “signaling hub” where different extracellular growth and survival signals converge. EGFR can be transactivated in response to multiple heterologous ligands through the physical interaction with multiple receptors, the activity of intracellular kinases or the shedding of EGFR-ligands. In this article we review the crosstalk between the EGFR and other signaling pathways that could be relevant to liver cancer development and treatment.
Keywords: G protein-coupled receptor (GPCR); a desintegrin and metalloprotease (ADAM); transactivation; growth factor receptor G protein-coupled receptor (GPCR); a desintegrin and metalloprotease (ADAM); transactivation; growth factor receptor
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Berasain, C.; Ujue Latasa, M.; Urtasun, R.; Goñi, S.; Elizalde, M.; Garcia-Irigoyen, O.; Azcona, M.; Prieto, J.; Ávila, M.A. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers 2011, 3, 2444-2461.

AMA Style

Berasain C, Ujue Latasa M, Urtasun R, Goñi S, Elizalde M, Garcia-Irigoyen O, Azcona M, Prieto J, Ávila MA. Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer. Cancers. 2011; 3(2):2444-2461.

Chicago/Turabian Style

Berasain, Carmen; Ujue Latasa, María; Urtasun, Raquel; Goñi, Saioa; Elizalde, María; Garcia-Irigoyen, Oihane; Azcona, María; Prieto, Jesús; Ávila, Matías A. 2011. "Epidermal Growth Factor Receptor (EGFR) Crosstalks in Liver Cancer." Cancers 3, no. 2: 2444-2461.



Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert